Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Petrini, Mario
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance	Active, not recruiting	2	75	Europe	Ibrutinib, IMBRUVICA (commercial name)	Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.	DLBCL	07/24	07/27